Questions: Pharmaceutical Impurity and Related Substances Analysis

Question 1

An analytical method for related substances testing shows three impurity peaks baseline-resolved from the API. The method developer declares the method validated for regulatory submission. Which additional criterion is essential before this declaration is justified?

• A. Specificity: confirming no impurity co-elutes under the API peak itself, using peak purity analysis or spiking of known degradants
• B. Linearity: confirming the UV detector response is proportional to concentration for all three impurity peaks
• C. Ruggedness: confirming the method gives the same results on different HPLC instruments in different laboratories
• D. Precision: confirming impurity peak areas are reproducible across repeated injections on the same day

Answer: (A)

Baseline resolution between visible peaks does not guarantee that no impurity is hidden under the API peak. Specificity — confirmed by photodiode array peak purity analysis or by spiking the API solution with known degradation products generated by forced degradation — verifies that the main peak is chemically homogeneous. This is distinct from resolution between satellite peaks. The other criteria are real validation requirements but do not address this specific gap in the developer's reasoning.

Question 2

A genotoxic nitrosamine impurity is detected in a tablet drug at 0.06% — below the ICH Q3A reporting threshold of 0.10%. The development team argues no regulatory action is required. This reasoning is:

• A. Incorrect — genotoxic impurities fall under ICH M7, which sets intake-based limits far stricter than any Q3A percentage threshold, often ≤1.5 µg/day
• B. Correct — 0.06% is below the reporting threshold, so the impurity is analytically irrelevant under all applicable guidelines
• C. Incorrect — all impurities above 0.01% must be completely eliminated before any drug can be approved
• D. Correct — percentage-based thresholds apply uniformly to all impurity classes, including DNA-reactive compounds

Answer: (A)

ICH Q3A percentage thresholds apply to ordinary (non-genotoxic) impurities. DNA-reactive genotoxic compounds fall under the separate ICH M7 guideline, which imposes acceptable daily intake limits typically around 1.5 µg/day — far stricter than any percentage threshold. The nitrosamine recalls of valsartan, ranitidine, and metformin products demonstrated the real-world cost of applying only Q3A logic to genotoxic impurities. Percentage and intake-based limits are different frameworks designed for different risk profiles.

Question 3

Forced degradation (stress testing) studies are performed before analytical method validation to ensure the method can detect degradation products the API may form during shelf life.

• T. True
• F. False

Answer: True

Forced degradation deliberately exposes the API to heat, acid, base, oxidation, light, and humidity to generate potential degradation products in the laboratory before they appear in the actual product. The analytical method is then developed and validated to resolve and detect these known degradants. This sequence — generate first, then develop the method — ensures the method has the specificity needed to detect real-world degradation. A method validated without this step might pass all technical criteria yet fail to detect degradants that form during storage.

Question 4

Once a pharmaceutical impurity has been structurally identified by LC-MS and NMR, it can be immediately quantified precisely in routine quality control testing without further analytical work.

• T. True
• F. False

Answer: False

Structural identification is only the first step toward quantitative control. Before precise routine quantification, a reference standard of the impurity must be synthesized or obtained, and a quantitative analytical method must be validated for that specific impurity — including linearity, accuracy, limits of detection and quantitation, and specificity. Without a reference standard, only semi-quantitative estimates (impurity peak area relative to the API peak, using a correction factor) are possible. Regulatory dossiers require validated quantitative methods supported by characterized reference standards for each specified impurity.

Question 5

Why do ICH Q3A impurity thresholds depend on the daily dose of the drug rather than being fixed percentages that apply equally to all pharmaceuticals?

Model answer: Because patient risk from an impurity depends on the absolute daily intake — how many milligrams enter the body — not on what fraction it represents in the formulation. A 0.10% impurity in a 2 g/day drug delivers 2 mg/day; the same 0.10% in a 5 mg/day drug delivers only 0.005 mg/day — a 400-fold difference in exposure. Lower-dose drugs have tighter percentage thresholds so that the maximum acceptable absolute intake remains comparable across products regardless of potency.

The underlying logic is toxicological: regulatory thresholds aim to keep patient exposure below levels that would require toxicological qualification. By anchoring thresholds to daily intake rather than percentage, ICH guidelines apply consistent safety margins across drugs of widely different dose levels. This is also why genotoxic impurities — which pose risk at microgram/day levels — require absolute intake limits under ICH M7 rather than percentage-based reporting thresholds, since even a very small percentage of a high-dose drug could exceed the safe intake.